Innoviva Deferred Long Term Liab vs Total Stockholder Equity Analysis
INVA Stock | USD 15.26 0.27 1.80% |
Innoviva financial indicator trend analysis is infinitely more than just investigating Innoviva recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Innoviva is a good investment. Please check the relationship between Innoviva Deferred Long Term Liab and its Total Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.
Deferred Long Term Liab vs Total Stockholder Equity
Deferred Long Term Liab vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Innoviva Deferred Long Term Liab account and Total Stockholder Equity. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Innoviva's Deferred Long Term Liab and Total Stockholder Equity is -0.15. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Innoviva, assuming nothing else is changed. The correlation between historical values of Innoviva's Deferred Long Term Liab and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Innoviva are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Deferred Long Term Liab i.e., Innoviva's Deferred Long Term Liab and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | -0.15 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Innoviva's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Innoviva current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.At present, Innoviva's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 5.86, whereas Discontinued Operations is forecasted to decline to (89.7 M).
Innoviva fundamental ratios Correlations
Click cells to compare fundamentals
Innoviva Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Innoviva fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 724.8M | 999.6M | 926.4M | 1.2B | 1.2B | 1.3B | |
Total Stockholder Equity | 313.5M | 539.9M | 414.7M | 565.8M | 675.0M | 708.7M | |
Retained Earnings | (946.4M) | (722.0M) | (456.1M) | (204.9M) | (25.2M) | (26.4M) | |
Other Assets | 293.6M | 657.5M | 425.2M | 198.5M | 228.2M | 131.6M | |
Common Stock Shares Outstanding | 113.4M | 113.6M | 94.3M | 34.3M | 36.1M | 34.3M | |
Liabilities And Stockholders Equity | 724.8M | 999.6M | 926.4M | 1.2B | 1.2B | 1.3B | |
Other Stockholder Equity | 1.3B | 1.3B | 870.2M | 770.0M | 699.5M | 1.0B | |
Total Liab | 382.7M | 391.7M | 400.5M | 665.7M | 568.6M | 442.4M | |
Short Long Term Debt Total | 377.1M | 385.5M | 394.7M | 637.9M | 449.1M | 331.0M | |
Other Current Liab | 5.4M | 6.0M | 5.8M | (63.8M) | 28.9M | 30.4M | |
Total Current Liabilities | 5.4M | 6.1M | 5.8M | 38.8M | 38.1M | 25.0M | |
Other Liab | 586K | 219K | 106K | 84.2M | 75.8M | 49.3M | |
Property Plant And Equipment Net | 33K | 28K | 12K | 3.4M | 3.0M | 2.9M | |
Net Debt | 99.0M | 139.0M | 193.1M | 346.8M | 255.6M | 192.9M | |
Accounts Payable | 10K | 66K | 27K | 2.9M | 6.7M | 7.1M | |
Cash | 278.1M | 246.5M | 201.5M | 291.0M | 193.5M | 138.1M | |
Non Current Assets Total | 293.6M | 657.5M | 612.7M | 788.0M | 899.3M | 944.3M | |
Non Currrent Assets Other | 139.4M | 214K | 108K | 101.9M | 87.1M | 68.4M | |
Long Term Debt | 377.1M | 385.5M | 394.7M | 540.4M | 446.2M | 321.7M | |
Cash And Short Term Investments | 350.8M | 246.5M | 201.5M | 291.0M | 193.5M | 235.5M | |
Net Receivables | 79.4M | 93.9M | 110.7M | 64.1M | 84.1M | 88.3M | |
Common Stock Total Equity | 1.0M | 1.0M | 1.0M | 696K | 800.4K | 857.6K | |
Short Term Investments | 72.7M | 438.3M | 483.8M | 403.0M | 463.5M | 486.6M | |
Non Current Liabilities Total | 377.3M | 385.6M | 394.7M | 626.9M | 530.4M | 426.9M | |
Other Current Assets | 80.4M | 95.6M | 112.1M | 32.5M | 25.9M | 28.2M | |
Property Plant And Equipment Gross | 33K | 28K | 12K | 3.4M | 3.0M | 2.9M | |
Total Current Assets | 431.2M | 342.1M | 313.7M | 443.5M | 344.2M | 281.5M | |
Common Stock | 1.0M | 1.0M | 696K | 692K | 633K | 845.9K | |
Property Plant Equipment | 33K | 28K | 12K | 3.4M | 3.1M | 2.9M | |
Inventory | (79.4M) | (93.9M) | (110.7M) | 55.9M | 40.7M | 42.8M | |
Net Tangible Assets | 313.5M | 539.9M | 414.7M | 286.2M | 329.1M | 345.5M | |
Noncontrolling Interest In Consolidated Entity | 152K | 5.5M | 67.9M | 111.2M | 127.9M | 134.3M | |
Retained Earnings Total Equity | (1.5B) | (1.1B) | (722.0M) | (456.1M) | (524.6M) | (550.8M) | |
Long Term Debt Total | 574.4M | 382.9M | 377.1M | 385.5M | 443.3M | 463.7M | |
Capital Surpluse | 1.3B | 1.3B | 1.3B | 1.3B | 1.1B | 1.1B | |
Deferred Long Term Liab | 139.1M | 125.3M | 111.4M | 97.6M | 112.2M | 122.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Innoviva Stock analysis
When running Innoviva's price analysis, check to measure Innoviva's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innoviva is operating at the current time. Most of Innoviva's value examination focuses on studying past and present price action to predict the probability of Innoviva's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innoviva's price. Additionally, you may evaluate how the addition of Innoviva to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Innoviva's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.65) | Earnings Share 2.2 | Revenue Per Share 4.745 | Quarterly Revenue Growth 0.305 | Return On Assets 0.0712 |
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.